G70.2 Congenital and developmental myasthenia

Name of the Condition

• Congenital and developmental myasthenia

Summary

Congenital and developmental myasthenia refers to a group of inherited neuromuscular disorders present at birth or emerging in early childhood, characterized by muscle weakness and fatigue due to impaired neuromuscular transmission. These conditions result from genetic mutations affecting proteins at the neuromuscular junction, leading to disrupted communication between nerves and muscles.

Causes

The condition is caused by genetic mutations that affect proteins involved in neuromuscular junction function, such as acetylcholine receptors, acetylcholinesterase, or associated proteins. These mutations disrupt normal signal transmission, resulting in muscle weakness. Unlike acquired myasthenia gravis, congenital forms are not autoimmune but are inherited.

Risk Factors

• Family history of neuromuscular disorders
• Consanguinity (parents who are closely related)
• Inherited genetic mutations affecting neuromuscular junction proteins

Symptoms

• Muscle weakness that may be present at birth or develop in infancy
• Fatigue with activity, improving with rest
• Feeding difficulties (e.g., weak suck, poor swallowing)
• Respiratory muscle weakness in severe cases
• Ptosis (drooping eyelids) or ophthalmoparesis (eye muscle weakness)
• Delayed motor milestones (e.g., sitting, walking)

Diagnosis

Diagnosis involves clinical evaluation of muscle weakness patterns, genetic testing to identify specific mutations, electromyography (EMG) to assess neuromuscular transmission, and sometimes muscle biopsy. Blood tests for antibodies (e.g., anti-acetylcholine receptor antibodies) are typically negative, distinguishing it from acquired myasthenia gravis.

Treatment Options

• Acetylcholinesterase inhibitors (e.g., pyridostigmine) to enhance neuromuscular transmission
• 3,4-Diaminopyridine to improve signal release at the junction
• Supportive care, including physical therapy and respiratory support if needed
• Genetic counseling for families

Prognosis and Follow-Up

Prognosis varies by specific mutation and severity. Some forms are mild with stable symptoms, while others may progress. Regular follow-up with a neurologist is important to monitor muscle function, respiratory status, and response to treatment. Early intervention can improve outcomes.

Complications

• Respiratory failure due to weak respiratory muscles
• Feeding difficulties leading to malnutrition
• Delayed motor development affecting mobility
• Chronic fatigue impacting daily activities

Lifestyle & Prevention

• Physical therapy to maintain muscle strength and mobility
• Avoiding overexertion to prevent fatigue
• Monitoring for respiratory symptoms, especially during illness
• Genetic counseling for families planning future pregnancies

When to Seek Professional Help

Seek immediate medical attention if experiencing:

• Severe respiratory distress or difficulty breathing
• Sudden worsening of muscle weakness
• Inability to swallow or feed
• New onset of ptosis or double vision

Tips for Medical Coders

When coding G70.2 (Congenital and developmental myasthenia), ensure documentation supports the congenital or developmental onset, distinguishing it from acquired myasthenia gravis. Verify that genetic testing or clinical features confirm the diagnosis. Document any associated complications or treatment responses to support accurate coding.